Everest Approved for China Phase II trial of Trodelvy® in TROP-2 Cancers
March 31, 2021 at 05:02 AM EDT
Shanghai 's Everest Medicines said it is approved to conduct a China Phase II trial of Trodelvy® in patients with cancers that have high TROP-2 expression. Everest plans to enroll 180 patients with esophageal squamous cell carcinoma, gastric cancer and cervical cancer. In 2019, Everest acquired Greater China rights to Trodelvy in an agreement worth up to $835 million from Immunomedics, which was bought by Gilead. Last year, Everest began a registrational China Phase IIb trial of the candidate to treat metastatic triple-negative breast cancer. More details.... Stock Symbols: (HK: 1952) (NSDQ: GILD) Share this with colleagues: // //